Literature DB >> 17531171

Mechanisms of aPL-mediated thrombosis: effects of aPL on endothelium and platelets.

Mariano E Vega-Ostertag1, Silvia S Pierangeli.   

Abstract

Antiphospholipid antibodies (aPL) are associated with thrombosis and pregnancy loss in patients with systemic lupus erythematosus and antiphospholipid syndrome. Strong evidence demonstrates that aPL are pathogenic in vivo from studies that utilized animal models of thrombosis, endothelial cell activation, and pregnancy loss. However, the mechanisms by which aPL mediate disease are only partially understood, and our knowledge is limited by the polyspecificity of the antibodies, the multiple potential end-organ targets, and the variability of the clinical context in which the disease may present. This review discusses and summarizes the most current data available on molecular interactions and pathogenic mechanisms in antiphospholipid syndrome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531171     DOI: 10.1007/s11926-007-0031-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.686


  49 in total

1.  Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin.

Authors:  S S Pierangeli; R G Espinola; X Liu; E N Harris
Journal:  Circ Res       Date:  2001-02-02       Impact factor: 17.367

2.  Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies.

Authors:  Ricardo G Espinola; Silvia S Pierangeli; Azzudin E Gharavi; E Nigel Harris; Azzudin E Ghara
Journal:  Thromb Haemost       Date:  2002-03       Impact factor: 5.249

3.  Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes.

Authors:  M A Khamashta; E N Harris; A E Gharavi; G Derue; A Gil; J J Vázquez; G R Hughes
Journal:  Ann Rheum Dis       Date:  1988-10       Impact factor: 19.103

4.  Systemic endothelial cell markers in primary antiphospholipid syndrome.

Authors:  F M Williams; K Parmar; G R Hughes; B J Hunt
Journal:  Thromb Haemost       Date:  2000-11       Impact factor: 5.249

5.  C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils.

Authors:  Johann Wojta; Christoph Kaun; Gerlinde Zorn; Minoo Ghannadan; Alexander W Hauswirth; Wolfgang R Sperr; Gerhard Fritsch; Dieter Printz; Bernd R Binder; Georg Schatzl; Joerg Zwirner; Gerald Maurer; Kurt Huber; Peter Valent
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

6.  Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome.

Authors:  Gabriela Cesarman-Maus; Nina P Ríos-Luna; Arunkumar B Deora; Bihui Huang; Rosario Villa; Maria del Carmen Cravioto; Donato Alarcón-Segovia; Jorge Sánchez-Guerrero; Katherine A Hajjar
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

7.  Antiphospholipid antibodies and complement activation in patients with cerebral ischemia.

Authors:  W D Davis; R L Brey
Journal:  Clin Exp Rheumatol       Date:  1992 Sep-Oct       Impact factor: 4.473

8.  Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster.

Authors:  Milosz Jankowski; Ingrid Vreys; Christine Wittevrongel; Doris Boon; Jos Vermylen; Marc F Hoylaerts; Jef Arnout
Journal:  Blood       Date:  2002-09-05       Impact factor: 22.113

9.  Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'.

Authors:  Bianca C H Lutters; Ronald H W M Derksen; Winnie L Tekelenburg; Peter J Lenting; Jef Arnout; Philip G de Groot
Journal:  J Biol Chem       Date:  2003-06-13       Impact factor: 5.157

10.  Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.

Authors:  V Michael Holers; Guillermina Girardi; Lian Mo; Joel M Guthridge; Hector Molina; Silvia S Pierangeli; Ricardo Espinola; Liu E Xiaowei; Dailing Mao; Christopher G Vialpando; Jane E Salmon
Journal:  J Exp Med       Date:  2002-01-21       Impact factor: 14.307

View more
  11 in total

1.  Antiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice.

Authors:  Victoria Ulrich; Eddy S Konaniah; Wan-Ru Lee; Sadiksha Khadka; Yu-Min Shen; Joachim Herz; Jane E Salmon; David Y Hui; Philip W Shaul; Chieko Mineo
Journal:  J Am Heart Assoc       Date:  2014-10-14       Impact factor: 5.501

2.  Spontaneous coronary artery dissection presenting as an ischaemic stroke in a middle-aged man with anti-cardiolipin antibodies: a case report.

Authors:  Ns Rajendra; F Lim; N Shaukat
Journal:  J Med Case Rep       Date:  2010-03-24

Review 3.  Microthrombotic/microangiopathic manifestations of the antiphospholipid syndrome.

Authors:  Sonja Praprotnik; Dusan Ferluga; Alenka Vizjak; Anastazija Hvala; Tadej Avcin; Blaz Rozman
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

4.  Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways.

Authors:  Anastasia Lambrianides; Christopher J Carroll; Silvia S Pierangeli; Charis Pericleous; Ware Branch; Jurhee Rice; David S Latchman; Paul Townsend; David A Isenberg; Anisur Rahman; Ian P Giles
Journal:  J Immunol       Date:  2010-05-17       Impact factor: 5.422

5.  Characterization of antiphospholipid antibodies in chronic hepatitis B infection.

Authors:  Ji Young Huh; Dae Young Yi; Seong Gyu Hwang; Jin Jung Choi; Myung Seo Kang
Journal:  Korean J Hematol       Date:  2011-03-15

6.  Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium.

Authors:  Anastasia Sacharidou; Ken L Chambliss; Victoria Ulrich; Jane E Salmon; Yu-Min Shen; Joachim Herz; David Y Hui; Lance S Terada; Philip W Shaul; Chieko Mineo
Journal:  Blood       Date:  2018-03-02       Impact factor: 25.476

7.  Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome.

Authors:  Andreas Barratt-Due; Yngvar Fløisand; Hilde L Orrem; Ann K Kvam; Pål A Holme; Grethe Bergseth; Geir E Tjønnfjord; Tom E Mollnes
Journal:  Rheumatology (Oxford)       Date:  2016-04-22       Impact factor: 7.580

Review 8.  Antiphospholipid syndrome.

Authors:  Gerard Espinosa; Ricard Cervera
Journal:  Arthritis Res Ther       Date:  2008-12-15       Impact factor: 5.156

9.  Thrombotic antiphospholipid syndrome shows strong haplotypic association with SH2B3-ATXN2 locus.

Authors:  Eguzkine Ochoa; Mikel Iriondo; Ana Bielsa; Guillermo Ruiz-Irastorza; Andone Estonba; Ana M Zubiaga
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

10.  LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers.

Authors:  Eguzkine Ochoa; Mikel Iriondo; Carmen Manzano; Asier Fullaondo; Irama Villar; Guillermo Ruiz-Irastorza; Ana M Zubiaga; Andone Estonba
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.